Nachrichten zur Bristol-Myers Squibb Co. Aktie

Global Regenerative Medicine Market Outlook 2021-2026: Major Players are Amgen, Bristol Myers Squibb, Dendreon, F. Hoffmann-La Roche, Gilead Sciences, Novartis, Osiris, Organogenesis, and Vericel

DUBLIN, June 18, 2021 /PRNewswire/ -- The "Regenerative Medicine Market - Global Outlook and Forecast 2021-2026" report has been added…

Bristol Myers to pay more than $2 billion to Eisai in a deal for experimental cancer therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

UPDATE 1-Bristol-Myers, Eisai in up to $3.1 bln deal to develop cancer drug candidate

...(Adds details on agreement, background) June 17 (Reuters) - Bristol......…

Bristol-Myers and Eisai to jointly develop, market cancer drug

(Reuters) - Bristol-Myers Squibb Co and Eisai Co on Thursday entered into an agreement to jointly…

Bristol-Myers and Eisai to jointly develop, market cancer drug

...(Reuters) - Bristol-Myers Squibb Co and Eisai Co on Thursday......…

Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know

Bristol Myers Squibb (BMY) closed at $66.77 in the latest trading session, marking a -0.22% move from the prior day....…

Bristol-Myers Squibb Company declares $0.49 dividend

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

OpenText Appoints Ann M. Powell to Board of Directors

WATERLOO, Ontario, June 15, 2021 /PRNewswire/ -- OpenText™ (NASDAQ: OTEX), (TSX: OTEX), today announced the appointment of Ann M. Powell…

Exelixis (EXEL) & Bristol Myers Team Up for Genitourinary Cancers

Exelixis (EXEL) collaborates with Bristol Myers to evaluate its next-generation tyrosine kinase inhibitor in combination with immuno-oncology therapies in advanced…

Bristol-Myers Squibb Company (BMY) Investor Presentation - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Exelixis, Bristol Myers To Evaluate XL092-Immuno-oncology Therapies In Advanced Solid Tumors

NEW YORK CITY (dpa-AFX) - Exelixis Inc. (EXEL) said Monday that it has reached a clinical trial collaboration and supply…

Bristol Myers Squibb Stock Remains Undervalued After Positive Data From Clinical Trials

The stock price of Bristol Myers Squibb (NYSE: BMY) has seen a 3% rise in yesterdays trading session (Jun 10),…

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

Bristol Myers Squibb (BMY) closed the most recent trading day at $67.34, moving -0.07% from the previous trading session....…

Bristol Myers (BMY) Announces Data on CAR T Cell Therapy Breyanzi

Bristol Myers (BMY) announces positive data on CAR T cell therapy, Breyanzi, in the second-line setting for patients with relapsed…

Bristol-Myers Squibb: Undervalued, With 13% Upside

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BMY, Acceleron Announce New Data From Reblozyl Phase 2 Trial For Adults With NTD Beta Thalassemia

NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) and Acceleron Pharma Inc. (XLRN) announced Friday the first data from…

Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript)

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers Higher on Progress With Lymphoma-Drug Trial

Um den gesamten Artikel unter thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...…

BMY Reports Positive Results From Phase 3 Breyanzi Trial In Second-line Relapsed Or Refractory LBCL

NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) announced Thursday positive topline results from Phase 3 TRANSFORM trial evaluating…

Bristol Myers announces positive topline data for Breyanzi in B-cell Lymphoma as second-line therapy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol Myers CEO: Opdivo returning to growth this year

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Full interview with Bristol Myers Squibb CEO on sales growth, pipeline and more

Dr. Giovanni Caforio, Bristol Myers Squibb chairman and CEO, joined "Squawk on the Street" to discuss the company's cancer research,…

Bristol Myers Touts Opdivo Win in Esophageal Cancer, But Yervoy-Opdivo Combo Comes with Caution

China Nivolumab Markets Report, 2016-2020 & 2021-2025 Featuring Bristol-Myers Squibb, Medarex, & Ono Pharmaceuticals

DUBLIN, June 3, 2021 The "Investigation Report on Chinas Nivolumab Market 2021-2025" report has been added to ResearchAndMarkets.coms offering. According…

Bristol Myers Faces $6.4B Lawsuit Over Delayed Approval of Breyanzi Non-Hodgkin Lymphoma Drug: Reuters

Bristol-Myers sued for $6.4 billion in alleged delay in seeking FDA approval for Celgene drug

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Lawsuit says Bristol-Myers avoided $6.4 billion payment by delaying cancer drug

...NEW YORK (Reuters) - A new lawsuit claims Bristol-Myers Squibb Co......…

Bristol Myers (BMY) Gets EC Nod Opdivo+Yervoy in Mesothelioma

The European Commission approves Bristol Myers (BMY) Opdivo in combination with Yervoy for the first-line treatment of malignant pleural mesothelioma....…

$ 19.89 Billion growth expected in Antiviral Drugs Market during 2021-2025 | AbbVie Inc., Bristol-Myers Squibb Co., and F. Hoffmann-La Roche Ltd. Emerge as Major Vendors | Technavio

NEW YORK, May 31, 2021 /PRNewswire/ -- The antiviral drugs market is expected to grow by USD 19.89 billion during…

The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq

Heres a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week…

Bristol Myers wins FDA approval for expanded use of Zeposia in ulcerative colitis

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Agenus/Bristol-Myers Squibb Deal Makes For A Strong Buy

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol-Myers Squibb Company (BMY) Management Presents at 2021 UBS Global Healthcare Virtual Conference (Transcript)

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Xencor, Bristol Myers Ink License Deal To Use Xtend XmAb Technology To Treat COVID-19

NEW YORK CITY (dpa-AFX) - Biopharmaceutical company Xencor, Inc. (XNCR) announced Tuesday it has entered into a technology license agreement…

Xencor and Bristol Myers Squibb ink technology license agreement

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Bristol Myers Unveils More Positive Data On Ulcerative Colitis Candidate Zeposia

Bristol Myers Wins Positive Opinion From EU For Opdivo/Yervoy Combo In Colorectal Cancer

Bristol Myers wins positive opinion in Europe for Opdivo and Yervoy combo for colorectal cancer

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

BRISTOL MYERS SQUIBB CO: 8-K Report

8-K...…

The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks

Heres a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week…